Japanese Scientists in Breakthrough Discovery of Drug That Could Regrow Human Teeth by 2030

Now in human trials, it could revolutionize dentistry and be available by 2030 (image source)

In a medical breakthrough that could redefine dentistry, Japanese researchers have developed a drug—TRG-035—that can regrow human teeth. The drug, now in human trials at Kyoto University Hospital, has shown promising results in animal studies and could be available to the public by 2030.

“The idea of growing new teeth is every dentist’s dream,” said Dr. Katsu Takahashi, lead researcher at the Medical Research Institute Kitano Hospital in Osaka.

TRG-035 targets a protein called USAG-1, which naturally inhibits the growth of additional teeth beyond childhood. By blocking USAG-1, the drug reactivates dormant tooth buds—embryonic precursors to new teeth. It works by removing the barrier to tooth regeneration, which leads to dormant buds beginning to grow new teeth. The drug is administered via injection for systemic circulation.

“This drug could be a game-changer for children born without permanent teeth,” said Dr. Chengfei Zhang, clinical professor at the University of Hong Kong.

Before human trials, TRG-035 was tested on mice, ferrets, and dogs—all of which successfully grew new teeth. Ferrets, whose dental structure closely resembles humans, developed fully functional teeth. “We were over the moon when we saw the results in ferrets,” Takahashi added. The Phase 1 trial involves 30 adults aged 30–64 who are missing at least one tooth. The primary goal is to assess safety and dosage. If successful, future trials will include children with congenital tooth agenesis.

Dr. Katsu Takahashi: The Pioneer of Tooth Regrowth (image source)

“Expectations are high that our technology can directly extend healthy life expectancy,” Takahashi said.

With over 90% of Japanese seniors missing at least one tooth, TRG-035 could revolutionize dental care worldwide. Experts caution, however, that widespread use will require years of testing and regulatory approval. “This is not a sprint—it’s a series of ultra-marathons,” said Professor Angray Kang of Queen Mary University.